(Q37291354)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Clinical significance of extended-spectrum beta-lactamases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Alvaro Pascual

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

671-683

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Resistance in gram-negative bacteria: enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Extended-spectrum beta-lactamases: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

The CTX-M beta-lactamase pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

CTX-M: changing the face of ESBLs in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Minor extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum beta-lactamases in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Epidemiology of extended-spectrum beta-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Complex molecular epidemiology of extended-spectrum beta-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

A case-control study of risk factors associated with rectal colonization of extended-spectrum beta-lactamase producing Klebsiella sp. in newborn infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Klebsiella pneumoniae bloodstream infections among neonates in a high-risk nursery in Cali, Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinico-epidemiological features of infections caused by CTX-M type extended spectrum beta lactamase-producing Escherichia coli in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in tunisia caused by multiply drug resistantSalmonella wien producing SHV-2 beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Characterization of a nosocomial outbreak involving an epidemic plasmid encoding for TEM-27 in Salmonella enterica subspecies enterica serotype Othmarschen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum beta-lactamase in a neonatal unit in Sousse, Tunisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial outbreak of pediatric gastroenteritis caused by CTX-M-14-type extended-spectrum beta-lactamase-producing strains of Salmonella enterica serovar London

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial outbreak of extended-spectrum beta-lactamase-producing Salmonella isangi in pediatric wards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Ertapenem for the treatment of extended-spectrum β-lactamase-producing Gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

CTX-M: changing the face of ESBLs in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Treatment options for multidrug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Extended-spectrum -lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.671

21 January 2018

Identifiers

DOI

10.1586/14787210.6.5.671

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18847405%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference